Renalytix

Renalytix (LSE: RENX) (NASDAQ: RNLX) is listed as a New York City artificial intelligence company in the healthcare sector [1]. The company operates in the biotechnology research industry [3] and describes itself as the founder and global leader in bioprognosis for kidney health [2]. According to its profile, Renalytix has engineered a proprietary solution designed to enable early-stage progression risk assessment for kidney disease [2]. The company employs approximately 51 people [3].

Something wrong or missing? Send a correction. Fixed within 24 hours.